Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial

In postmenopausal women, 2  yr of combined teriparatide and denosumab increases bone mineral density more than either drug alone, and switching from either combination or teriparatide to denosumab for an additional 2 yr further increases bone mineral density. Conversely, switching from denosumab to teriparatide results in transient bone loss. The effects of these interventions on spine microarchitecture are unknown. In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 µg daily), denosumab (60 mg every 6 mo), or both.

Source: Journal of Clinical Densitometry - June 14, 2017 Category: Radiology Authors: Joy N. Tsai, Linda A. Jiang, Hang Lee, Didier Hans, Benjamin Z. Leder Tags: Original Article Source Type: research